KBY Biotech Indexv0.0.34
Search
← Pipeline|APT-892

APT-892

Approved
By Aptinyx
Source: Trial-derived·Trials: 4
Modality
Bispecific Ab
MOA
BiTE
Target
PD-1
Pathway
Cell Cycle
CholangiocarcinomaPNHMeso
Development Pipeline
Preclinical
~Jun 2011
→ ~Sep 2012
Phase 1
~Dec 2012
→ ~Mar 2014
Phase 2
~Jun 2014
→ ~Sep 2015
Phase 3
~Dec 2015
→ ~Mar 2017
NDA/BLA
~Jun 2017
→ ~Sep 2018
Approved
Dec 2018
→ Jan 2029
ApprovedCurrent
NCT08361093
2,509 pts·Cholangiocarcinoma
2024-04→2025-11·Terminated
NCT03217716
733 pts·Meso
2023-11→2027-10·Terminated
NCT05164390
1,533 pts·Meso
2018-12→2029-01·Terminated
+1 more trial
6,193 total pts3 indications
CompletedCurrentUpcoming
Catalysts (4)
2025-11-184mo agoPh3 Readout· Cholangiocarcinoma
2027-10-251.6y awayPh3 Readout· Meso
2028-07-052.3y awayPh3 Readout· PNH
2029-01-082.8y awayPh3 Readout· Meso
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
Approved
Termina…
Approved
Recruit…
Approved
Termina…
Approved
Termina…
Catalysts
Ph3 Readout
2025-11-18 · 4mo ago
Cholangiocarcinoma
Ph3 Readout
2027-10-25 · 1.6y away
Meso
Ph3 Readout
2028-07-05 · 2.3y away
PNH
Ph3 Readout
2029-01-08 · 2.8y away
Meso
RecruitingTerminated|StartCompletionToday
Trials (4)
NCTPhaseIndicationStatusNEP
NCT08361093ApprovedCholangiocarcinomaTerminated2509EDSS
NCT03217716ApprovedMesoTerminated733UPCR
NCT05164390ApprovedMesoTerminated1533CR
NCT07074603ApprovedPNHRecruiting1418UPCR
Competitors (10)
DrugCompanyPhaseTargetMOA
JNJ-7458Johnson & JohnsonPhase 1/2PD-1JAK1i
LLY-3251Eli LillyPhase 2MDM2BiTE
ZanutinibBristol-Myers SquibbPhase 2/3APOC3BiTE
BemarelsinDaiichi SankyoPreclinicalGLP-1RBiTE
PexaosocimabDaiichi SankyoPhase 2PD-1JAK1i
DSN-7360Daiichi SankyoApprovedSGLT2BiTE
MRN-8133ModernaPhase 2PD-1BTKi
BII-8315BiogenNDA/BLACDK2BiTE
SemazasiranBeiGenePhase 1PD-1FXIai
GeliglumideSamsung BiologicsPhase 1AβBiTE